Stay informed with the latest litigation news. Explore now

Isis Pharmaceuticals competitive analysis

Latest publications and patents of Isis Pharmaceuticals New

Explore the latest publications and patents granted to Isis Pharmaceuticals, showcasing their recent innovations and technological advancements.

Last updated on: Sep 1, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Isis Pharmaceuticals

Dec 14, 2022Methods For Modulating C9Orf72 ExpressionPatent Maintained As Amended
Jun 10, 2020Linkage Modified Gapped Oligomeric Compounds And Uses ThereofPatent Maintained As Amended
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral PolymeraseRevoked
Dec 26, 2018Modulation Of Alpha Synuclein ExpressionRevoked
Aug 15, 2018Modulation Of Ube3A-Ats ExpressionRevoked
Feb 7, 2018Modulation Of Apolipoprotein Ciii (Apociii) ExpressionRevoked
Jan 17, 2018Oligomeric Compounds Comprising Tricyclic Nucleosides And Methods For Their UseNo Opposition Filed Within Time Limit
Jan 3, 2018Oligomeric Compounds Comprising Bicyclic Nucleotides And Uses ThereofNo Opposition Filed Within Time Limit
Nov 15, 2017Modulation Of Rna By Repeat TargetingRevoked

Explore Isis Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 4, 2025
Patent NumberGrant DateTitleTotal Oppositions
Dec 14, 2022Methods For Modulating C9Orf72 Expression2
Jun 10, 2020Linkage Modified Gapped Oligomeric Compounds And Uses Thereof1
Apr 29, 2020Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase1
Dec 26, 2018Modulation Of Alpha Synuclein Expression1
Aug 15, 2018Modulation Of Ube3A-Ats Expression1
Feb 7, 2018Modulation Of Apolipoprotein Ciii (Apociii) Expression2
Nov 15, 2017Modulation Of Rna By Repeat Targeting1

Top competitors of Isis Pharmaceuticals

Top competitors of Isis Pharmaceuticals based on patent oppositions.